| June 23 Monday |
| Ion Channels as Pain Targets |
| 8:35 |
Chairman's remarks |
| 8:40 |
Torben Neelands
Abbott Laboratories
Apparent Voltage-Dependence of A-425619, a Competitive TRPV1 Antagonist, is Due to Voltage-Dependent Capsaicin Potency at Human TRPV1 Receptors
download presentation |
| 9:10 |
Aaron Gerlach
Icagen
KCNQ Channels: Drug Discovery Targets for the Treatment of Epilepsy and Pain |
| 9:40 |
Jeff Clare
Director, R&D
Ion Channel Group,
Millipore
Targeting voltage-gated sodium channels for pain therapy
download presentation |
| 10:10 |
Zhiyuan Li
Investigator and Head of Ion Channels Research Laboratory
Guangzhou Institute of Biomedicine and Health, Chinese
Academy of Sciences
Discovery of M2 Antagonists for New Antiviral drugs |
| 10:40 |
Break |
| Ion Channels as Disease Targets |
| 11:05 |
Chairman's remarks |
| 11:10 |
Yi-Xin Qian
Amgen
Discovery of kv1.3 blockers for autoimmune diseases |
| 11:40 |
Steve Goldstein
University of Chicago
Professor, Pediatrics, Physiology, Neurobiology and Molecular Medicine
Founding Director, Institute of Molecular Pediatric Sciences
Co-Director, Institute for Translational Medicine
University of Chicago, Pritzker School of Medicine
Improving on nature: designer toxins from animal venom scaffold expression libraries |
| 12:10 |
Lunch |
| 1:30 |
Alexei Bagrov
National Institute on Aging, NIH
Digitalis-like cardiotonic steroids; clinical and therapeutic applications
download presentation
|
| 2:00 |
Elizabeth Tringham
Neuromed Technologies
T-type channel blockers as a novel
antiepileptic therapy |
| 2:30 |
Jesus "Tito" Gonzales
Sr. Director, Ion Transport
Vertex Pharmaceuticals
CFTR Modulators for Treating Cystic Fibrosis |
| 3:00 |
Gary Desir
Yale University
Kv1.3 and Synaptotagmin-7 Regulates Calcium-Dependent GUT4 traffic |
| 3:30 |
Break |
| 3:45 |
Gail Robertson
Associate Professor, Department of Physiology
University of Wisconsin
Physiology and Pharmacology of hERG 1a/1b Channels: Implications for Inherited and Acquired Long QT Syndrome |
| Ion Channel Screening Technologies |
| 4:15 |
Chairpersons remarks |
| 4:20 |
Dr. Steve Smith
Chantest
Reading the ion channel library with QPatch-HT |
| 4:50 |
Howard Zhang
Wyeth Research
NeuroScience Discovery
Validation of Quattro IonWorks Assays for Screening of State-Dependent Nav1.7 Blockers |
| |
| June 24 Tuesday |
| Ion Channel Screening Technologies |
| 8:30 |
Chairpersons remarks |
| 8:35 |
Xueying Cao
Preclinical Safety Profiling/LFP, US
Novartis Institutes for BioMedical
Research, Inc.
Optimization of the QPatch Assay for "High Throughput" hERG Inhibition
download presentation |
| 9:05 |
Steve Hess
Research Fellow
Invitrogen
Building Robust Ion Channel Assays for Lead Discovery and Safety Liability Assessment |
| 9:35 |
Sikander Gill
Director of Assay Development
Aurora Biomed
Development of Screening Technology Using Synthetic Lipid Vesicles and ICR |
| 10:05 |
Cristian Ionescu-Zanetti
Chief Scientific Officer
Fluxion
Enabling “Plate Reader” Simplicity in High Throughput Electrophysiology through Well Plate Integration with Microfluidics |
| 10:35 |
Kun Lui
Wyeth Research
Cardiovascular and Metabolic Diseases
Voltage gated K+ channel blockers: from assay development to lead identification |
| 11:05 |
Lazslo Kiss
Senior Research Fellow
Merck Research Laboratories
High Throughput Electrophysiology Screen of a 200K Library to Identify Delayed Rectifier Potassium Channel Inhibitors |
| 11:35 |
Lunch |
| Ion Channels in Safety Screening |
| 12:45 |
Chairpersons Remarks |
| 12:50 |
Jean-Pierre Valentin
Director, Safety Pharmacology, Safety Assessment UK
AstraZeneca
Adverse Drug Reactions Link To Ion Channels Dysfunction |
| 1:20 |
Fraser Moss
Postdoctoral Fellow
Div. Biology, California Institute of Technology
hERG K+ Channel Drug Block Underlying Acquired Long-QT Syndrome Probed With Natural And Unnatural Amino Acid Mutagenesis In Mammalian Cells |
| 1:50 |
Arthur "Buzz" Brown
Chairman and CEO
Chantest
Channel Panel for Safety and Discovery Profiling
download presentation |
| 2:20 |
Ralf Kettenhofen
Scientist
Axiogenesis AG
ES-derived Cardiomyocytes: A New, Predictive Tool for Drug Development and Safety Pharmacology
download presentation |
| |
| June 25 Wednesday |
| Structure and Function |
| 8:30 |
Chairpersons remarks |
| 8:35 |
Craig January
Professor of Medicine and Physiology
University of Wisconsin
Cellular Dynamics
International, Inc.
A Constitutively Open hERG K+ Channel |
| 9:20 |
Jerrel Yakel
Senior Investigator
NIH/NIEHS
Structural determinates for apolipoproteinE–derived peptide interaction with the a7 nicotinic acetylcholine receptor :structural transitions triggered by agonist binding that induce channel opening.
download presentation |
| 9:50 |
Jianmin Cui
Associate Professor, Spencer T. Olin Endowment Department of Biomedical Engineering
Washington University of St. Louis
The Interaction between the Voltage-Sensor and Cytosolic Domains in BK channel Activation and Its Modulation by Mg2+ |
| 10:20 |
Break |
| 10:50 |
Vladislav Zarayskiy
Boston University
ADAR-mediated RNA editing of Orai1 is a key to different selectivity of store-operated channels |
| 11:20 |
Min Li
Professor, Dept. of Neuroscience & High Throughput Biology Center
Johns Hopkin School of Medicine
Chemical activation of voltage-gated potassium channels |
| 11:50 |
John Adelman
Professor
Oregon Health and Science University
TBA |
| 12:20 |
Lunch |
| 1:30 |
Jun Chen
Neuroscience Research
Abbott Laboratories
Molecular determinants of species-specific activation or blockade of TRPA1 channels |
| 2:00 |
Andreas Jeromin
Manager, Methods Development
Allen Institutes for Brain Science
Single-molecule tracking and total-internal reflectance microscopy to monitor the membrane dynamics and organization of Kv4.2 |
| 2:30 |
Kewei Wang
Peking University and ChemPartner
Structural Insights into Kv4 K+ Channel Modulation by Auxiliary KChIP Subunits |
| 3:00 |
Dong Liang
CEO
Aurora Biomed Inc.
Closing Remarks |
